Immunic to present MS data at Toronto meeting

Immunic said four abstracts on vidofludimus calcium were accepted for presentation at the MSToronto2026 multiple sclerosis meeting in Toronto later this month. The company also cited new Phase 2 CALLIPER open-label extension data and exploratory biomarker and preclinical findings.